24,526 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Machina Capital S.A.S.

Machina Capital S.A.S. bought a new stake in shares of Royalty Pharma plc (NASDAQ:RPRX) in the fourth quarter, Holdings Channel reports. The fund bought 24,526 shares of the biopharmaceutical company’s stock, valued at approximately $689,000.

Several other large investors have also recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. raised its stake in Royalty Pharma by 13.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 9,840,000 shares of the biopharmaceutical company’s stock valued at $267,058,000 after buying an additional 1,190,000 shares during the last quarter. Morgan Stanley grew its holdings in shares of Royalty Pharma by 1.5% during the third quarter. Morgan Stanley now owns 48,132,615 shares of the biopharmaceutical company’s stock valued at $1,306,319,000 after buying an additional 702,754 shares during the last quarter. California Public Employees Retirement System boosted its stake in Royalty Pharma by 49.2% during the 3rd quarter. California Public Employees Retirement System now owns 2,026,131 shares of the biopharmaceutical company’s stock valued at $54,989,000 after purchasing an additional 667,827 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Royalty Pharma by 1.5% in the third quarter. Vanguard Group Inc. now owns 39,437,354 shares of the biopharmaceutical company’s stock worth $1,070,330,000 after purchasing an additional 589,558 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in shares of Royalty Pharma by 45.1% during the third quarter. Qube Research & Technologies Ltd now owns 1,710,872 shares of the biopharmaceutical company’s stock valued at $46,433,000 after purchasing an additional 531,529 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of recent analyst reports. The Goldman Sachs Group dropped their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. JPMorgan Chase & Co. reduced their target price on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Thursday, April 11th. Finally, Bank of America lowered their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, April 12th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Royalty Pharma presently has an average rating of “Buy” and an average price target of $46.75.

Royalty Pharma Price Performance

NASDAQ:RPRX traded up $0.08 during trading hours on Monday, reaching $28.49. The stock had a trading volume of 1,860,971 shares, compared to its average volume of 2,699,988. The stock has a market capitalization of $17.02 billion, a PE ratio of 15.07 and a beta of 0.47. The company has a 50 day moving average price of $29.31 and a two-hundred day moving average price of $28.59. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90. Royalty Pharma plc has a 52 week low of $25.92 and a 52 week high of $35.70.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The firm had revenue of $736.00 million for the quarter, compared to the consensus estimate of $702.90 million. As a group, sell-side analysts anticipate that Royalty Pharma plc will post 3.95 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date is Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is 44.44%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.